• Explore /
  • Poster
  • / A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors.

A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors.

Abstract Poster

Authors

null

Benjamin L. Schlechter

Dana-Farber Cancer Institute, Boston, MA;

Benjamin L. Schlechter , Daniel Olson , Samuel Saibil , Mridula Annette George , Kelly Gruber , Riemke Bouvier , Brooke Pieke , Jill Geisburger , Kara M. Moss , Nathan Ternus , Deyaa R Adib , Ecaterina Elena Dumbrava

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04727151

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS816)

DOI

10.1200/JCO.2023.41.4_suppl.TPS816

Abstract #

TPS816

Poster Bd #

P6

Abstract Disclosures

Similar Posters

First Author: Benjamin L. Schlechter

First Author: Apostolia Maria Tsimberidou

First Author: Apostolia Maria Tsimberidou

First Author: Allison Graeter